RxDoctor Payments Data

Heather Dawson, MD

Family Medicine · Charleston, SCNPI 1396705034

Payments from drug & device makers

$2,955in general payments, 2019–2025

Across 102 payments — averaging $28.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$971
  • Lilly USA, LLC$409
  • Exact Sciences$308
  • GSK$255
  • Novo Nordisk$241
  • Bayer$169
  • plus $601 from 18 others

What the payments were for

  • Food & beverage$2,955100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,955 in reported general payments places this provider in the 75th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$115,642
Medicare patients
144
Services billed
3,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide44$64,066
EliquisApixaban74$63,400
OzempicSemaglutide51$53,806
Breztri AerosphereBudesonide/Glycopyr/Formoterol45$35,432
RybelsusSemaglutide13$34,641
TrulicityDulaglutide24$34,456
JardianceEmpagliflozin27$30,936
JanuviaSitagliptin Phosphate25$30,839
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$26,167
MyrbetriqMirabegron19$17,253
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl85$13,533
Spiriva RespimatTiotropium Bromide17$13,343
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$8,215
Spiriva HandihalerTiotropium Bromide15$7,730
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$4,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$409$98,52268 claims
Novo NordiskOzempic, Rybelsus$241$88,44764 claims
PfizerEliquis$42$63,40074 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat$28$52,49461 claims
AstraZenecaBreztri Aerosphere$971$35,43245 claims
GSKTrelegy Ellipta$255$26,16732 claims
Sanofi-aventis U.S. LLCLantus$68$1,37913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →